Lineage Cell Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Foreign
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Tax Assets, Operating Loss Carryforwards, Foreign of $3.60 million as of 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign · last filed 2021-03-11
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $3.60M.
- 2019-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $84.80M.
- 2018-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $72.90M.
- 2017-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $65.20M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Foreign |
|---|---|
| 2020-12-31 | $3.60M 10-K · filed 2021-03-11 |
| 2019-12-31 | $84.80M 10-K · filed 2020-03-12 |
| 2018-12-31 | $72.90M 10-K · filed 2019-03-14 |
| 2017-12-31 | $65.20M 10-K · filed 2018-03-15 |
| 2014-12-31 | $54.21M 10-K · filed 2015-03-11 |
| 2013-12-31 | $48.40M 10-K · filed 2014-03-17 |
| 2012-12-31 | $48.80M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |